Overview
A new era of cures
Biotherapies are the future of medicine — a future that is being created at Mayo Clinic.
The Mayo Clinic Center for Regenerative Biotherapeutics accelerates the clinical translation of new biotherapies to early-phase clinical trials. We are at the forefront of biomanufacturing, focusing on engineered cell therapy and tissue engineering, including bioprinting. We translate groundbreaking discoveries into new therapies for patients at Mayo Clinic and beyond.
What is biomanufacturing?
The Center for Regenerative Biotherapeutics is Mayo’s hub for biomanufacturing, a type of manufacturing that draws on materials from the human body — cells, blood, enzymes, tissues, genes or genetically engineered cells — for use in medicines. Biotherapies have the potential for targeted healing with fewer side effects than those of traditional medicines.
For example, biomanufacturing can allow doctors to create personalized medicines for specific patients and then change and improve them as needed. “It is absolutely essential to our research to have biomanufacturing facilities on-site, near the patient, in case we need to make adjustments based on each patient’s individual tumor that could better kill cancer cells,” says Keith L. Knutson, Ph.D., a Mayo Clinic cancer researcher.
Or biomanufacturing can be used to create vaccines for people who may be at risk of certain types of cancer. “That’s what makes our research unique from a scientific standpoint. The study participant can walk over to the lab and have the blood drawn, and within hours, the specimen can be transferred to the on-site facility where the process of biomanufacturing the vaccine begins,” adds Matthew S. Block, M.D., Ph.D.
Collaborating across and beyond Mayo Clinic
The Center for Regenerative Biotherapeutics’ mission is to translate Mayo Clinic discoveries into early-phase clinical trials to support new cures for patients. The center provides biomanufacturing capabilities and infrastructure to advance practice and research priorities in the areas of immunotherapeutics for cancer and other illnesses, transplant innovation, and surgical and procedural innovation.
The center is seeking collaboration opportunities with external organizations — industry partners, academic institutions and biotech companies — to codevelop and advance the progress of new regenerative treatments and therapies for patients. We invite collaborators to leverage our clinical expertise, manufacturing infrastructure and capabilities, and robust clinical trial infrastructure.
Our experts evaluate the scientific quality of new discoveries so that we can scale up production, streamline biomanufacturing and lower the cost of new medicines. We do this by using automation in line with industry best practices and driven by patient need.